Neumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Update

Neumora Therapeutics, Inc. (NASDAQ:NMRA) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 8,860,000 shares, an increase of 21.4% from the June 30th total of 7,300,000 shares. Approximately 16.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 788,400 shares, the days-to-cover ratio is currently 11.2 days.

Neumora Therapeutics Trading Up 2.9 %

Shares of Neumora Therapeutics stock traded up $0.36 during trading hours on Tuesday, reaching $12.81. 719,576 shares of the company’s stock were exchanged, compared to its average volume of 617,601. Neumora Therapeutics has a 52-week low of $8.33 and a 52-week high of $21.00. The company has a fifty day moving average of $10.23 and a 200-day moving average of $12.76.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.34) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.34). Analysts anticipate that Neumora Therapeutics will post -1.46 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Amalgamated Bank purchased a new position in shares of Neumora Therapeutics in the 4th quarter worth $29,000. Tower Research Capital LLC TRC purchased a new position in shares of Neumora Therapeutics in the 4th quarter worth $44,000. Strs Ohio purchased a new position in shares of Neumora Therapeutics in the 4th quarter worth $54,000. SG Americas Securities LLC purchased a new position in shares of Neumora Therapeutics in the 4th quarter worth $108,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Neumora Therapeutics in the 4th quarter worth $118,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NMRA has been the topic of a number of analyst reports. Needham & Company LLC initiated coverage on Neumora Therapeutics in a report on Monday, July 22nd. They set a “buy” rating and a $23.00 target price on the stock. Mizuho initiated coverage on Neumora Therapeutics in a report on Monday, July 8th. They set an “outperform” rating and a $20.00 target price on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Neumora Therapeutics in a report on Friday, April 12th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $22.33.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.